Mortality

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Disease, Super Meat Boy, Serum, Coronary artery disease, IL-6, Inflammation, Patient, Mortality, Death, NLRP3, ASC, Therapy, Inflammasome, CAD, Pharmaceutical industry

The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.

Key Points: 
  • The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.
  • WESTON, Fla., April 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc .
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a peer-reviewed article published in Biochemical and Biophysical Research Communications.
  • This article demonstrates that NLRP3 inhibition results in improved glucose tolerance and markedly smaller and more stable atherosclerotic lesions in a diabetic mouse model.

Philips Foundation and March of Dimes partner to improve prenatal care access in underserved communities, helping address US maternal and infant health challenges

Retrieved on: 
Thursday, April 4, 2024
Research, Health, Partnership, Education, Patient, Hospital, Prenatal care, Mortality, Infant, Pregnancy, Birth, Woman, Community, Safety, Nursing

In comparison to other high-income countries, the US still faces the highest maternal mortality rate.

Key Points: 
  • In comparison to other high-income countries, the US still faces the highest maternal mortality rate.
  • While consistent, high-quality prenatal care is an essential component of maternal health and positive birth outcomes, more than 550,000 women receive inadequate prenatal care in the US each year.
  • Mobile healthcare delivery is a proven model to improve access to care.
  • “Every expectant mother should have access to maternal care, yet this is far from reality today.

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Retrieved on: 
Thursday, April 4, 2024
Disease, MSSA, MRSA, Development, TARGET, Associate, Partnership, CABP, New Drug Application, Patient, HHS, Mortality, NDA, Fungal infection, Staphylococcus aureus, Bronchopneumonia, Infection, Safety, SAB, ASPR, Staphylococcus, Ceftobiprole, Administration, FDA, ABSSSI, Pharmaceutical industry

David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.

Key Points: 
  • David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.
  • The positive decision by the FDA is a key milestone towards bringing ZEVTERA to patients in the US.
  • This approval is a landmark for ceftobiprole and reflects its broad clinical utility.
  • Through this partnership, Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work.

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
Wednesday, April 3, 2024
Cardiorenal syndrome, Congestion, DSR, Brussels Stock Exchange, Liver disease, Associate, RED, Patient, NYHA, Mortality, Cancer, Fluid, Heart failure, European Journal, Diuretic, Overload, Syndrome, Yale University, Pharmaceutical industry

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

Spectral Medical Chair to Retire From the Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Sepsis, Chair, Mortality, Septic shock, PMX, TSX, Retirement, Management

Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010.

Key Points: 
  • Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010.
  • Mr. Bihl will step down as Chair, effective April 2, 2024, but will remain a director until his retirement from the board in June.
  • “It has been my pleasure to serve Spectral for 16 years, including the last 14 years as Chairman.
  • I have been fortunate to work with Tony for the last three years and I wish him well for the future,” said Chris Seto, CEO of Spectral Medical.

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Retrieved on: 
Tuesday, April 2, 2024
Psilocybin, Methamphetamine, Public health, Psychotherapy, Research, Mortality, University, RVV, DSM-IV codes, IND, Safety, Therapy, Disorder, OTCQB, Study, School, Pharmaceutical industry

The Study has enrolled nearly 50% of its intended study sample, with initial efficacy being encouraging.

Key Points: 
  • The Study has enrolled nearly 50% of its intended study sample, with initial efficacy being encouraging.
  • The clinical data generated from the Study may provide proprietary and valuable information on the safety, efficacy and dosing of oral psilocybin to support a potential pivotal clinical study and commercial initiatives in countries, such as Australia, where psilocybin can be available to licensed psychiatrists to prescribe for certain conditions.
  • Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality.
  • At present, there are no approved medications to treat methamphetamine use disorder.

National Study: Ballad Health, ETSU Trauma Consolidation Saves Hundreds of Lives

Retrieved on: 
Monday, April 1, 2024
Trauma center, Level 3, Learning, Survival, Incidence, Partnership, Stunning, Ballad Health, Patient, Trauma, Research, Mortality, Lead, University, Death, Health, Injury, Johnson City Medical Center, Investment, Emergency medical services, Nursing, Patient safety, ICU, ETSU, Trauma Center, Physician, Rehabilitation, Hospital

In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.

Key Points: 
  • In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.
  • It found the patients with the highest likelihood of death due to severity had significantly improved survival rates post-consolidation.
  • Assisted by national experts, the advisory group recommended consolidation of the region’s two Level 1 trauma centers into one at Johnson City Medical Center, while maintaining Level 3 trauma services at Holston Valley Medical Center and Bristol Regional Medical Center.
  • “Excellent trauma care is a team effort from every corner of our region,” said Ballad Health Chairman and CEO Alan Levine.

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024
Regeneration, Exercise, Exchange, Patient, SAN, Column, Sale, Mortality, LLP, Public expenditure, Security (finance), Cooley LLP, Guggenheim Partners, Crosstalk (biology), P.C, Therapy

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN, SRZNW), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock. If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock. The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.

Key Points: 
  • If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock.
  • The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
  • The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.
  • Guggenheim Securities, LLC is acting as sole placement agent for the private placement and is being advised by Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.

Security National Financial Corporation Reports Financial Results for the Year Ended December 31, 2023

Retrieved on: 
Monday, April 1, 2024
SNFC, Tax, Growth, Environment, Mortality, Acquisition, Death

SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the year ended December 31, 2023.

Key Points: 
  • SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the year ended December 31, 2023.
  • For the twelve months ended December 31, 2023, SNFC’s after-tax earnings from operations decreased 44% from $25,690,000 in 2022 to $14,495,000 in 2023, on a 18% decrease in revenues to $318,497,000.
  • Scott Quist, Chairman of the Board, President, and Chief Executive Officer of SNFC, said, “2023 was a year where the financial balance of our company demonstrated itself.
  • The following table shows the revenues and earnings before taxes for the twelve months ended December 31, 2023, as compared to 2022, for each business segment:

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Civil service commission, Research, AATD, Growth, Akari, C5, Patient, Choroidal neovascularization, Sale, B4, PRV, Mortality, Hot game, Clinical trial, Therapy, Priority review, Safety, NEI, European Commission, ADC, Geographic atrophy, Hematopoietic stem cell transplantation, CNV, Pharmaceutical industry

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

Key Points: 
  • BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
  • The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
  • Akari is continuing to recruit patients into the Part A portion of the Phase 3 clinical trial that has treated 10 patients to date.
  • During 2023, Akari also advanced the long-acting version of nomacopan (PASylated nomacopan) into the final stages of pre-clinical development as a treatment for geographic atrophy (GA).